Antiplatelet Use in the Setting of Therapeutic Anticoagulation: A Scoping Review

Authors: Ammar, Amina; Edwin, Stephanie B; Reed, Jason B; Kaatz, Scott; Barnes, Geoffrey D; Giuliano, Christopher

Source journal: Pharmacotherapy (2026-12-01)

DOI: 10.1002/phar.70220

Abstract

Patients receiving therapeutic oral anticoagulation (OAC) often have indications for antiplatelet therapy. Historically, antiplatelet agents have been used alongside therapeutic anticoagulation, increasing the risk of bleeding without a proven reduction in thrombosis. This scoping review summarizes recent evidence evaluating OAC monotherapy compared with combination therapy consisting of OAC plus antiplatelet agent among patients with atrial fibrillation and stable coronary artery disease, cerebrovascular disease, and prosthetic heart valves. We searched PubMed, Embase, CENTRAL, and International Pharmaceutical Abstracts to identify randomized controlled trials (RCTs) evaluating these strategies. Included studies enrolled adults receiving therapeutic anticoagulation across different cardiovascular disease states that reported efficacy and safety outcomes. Two reviewers independently screened studies and extracted data, with disagreements resolved by a third reviewer. Published subgroup analyses of included RCTs were also reviewed. After screening 10,008 records, 11 RCTs met inclusion criteria. Evidence supporting OAC monotherapy was observed in patients with atrial fibrillation and stable coronary artery disease; OAC monotherapy consistently reduced bleeding without increasing ischemic events compared with combination therapy. Similar reductions in bleeding were observed in patients with cerebrovascular disease, although evidence remains limited by small sample size and early trial termination. Among patients undergoing transcatheter aortic valve replacement with an indication for chronic anticoagulation, OAC monotherapy reduced bleeding without compromising ischemic outcomes. Evidence supporting discontinuation of antiplatelet therapy in patients with mechanical heart valves remains limited. Additional RCTs are needed to better define the role of antiplatelet therapy in cerebrovascular disease, prosthetic heart valves, and other high-risk populations.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.